You are here
Uptick Newswire Welcomes William Hartman, CEO of Premier Biomedical, Inc. Back on to the “Stock Day” Podcast
PHOENIX, June 04, 2018 (GLOBE NEWSWIRE) -- William Hartman, CEO of Premier Biomedical, Inc. (OTC Pink:BIEI) (“the Company”) was recently interviewed by Marcus Heatherly on Uptick Newswire’s “Stock Day” podcast. He discussed the company’s history, recent participation in the Sorinex Summer Strong event, the science behind their CBD-based products, and exciting plans for the company’s future.
Premier Biomedical, Inc. has evolved since its inception in 2010. The company first went public in 2012, and in 2013 the leadership team signed a Cooperative Research and Development Agreement with the Department of Defense to develop a treatment for PTSD together with the University of Texas at El Paso.
Premier Biomedical is a very broad company, and their research spans multiple topics within the biomedical field. The company has been working on a treatment and cure for PTSD, anti-cancer drugs, and their line of over-the-counter pain management products containing hemp-based CBD oil.
In 2017, Premier Biomedical developed five CBD-based pain relief products including a 96-hour topical skin patch, two varieties of roll-on applicators, a spray, and an ointment, all with more CBD content than principal competition. Extra-strength versions of these products were debuted at the Sorinex Summer Strong Event last week. These new Extra-Strength products are believed to have the highest levels of CBD available on the market. All of BIEI’s pain relief products are available for purchase through the company’s website, www.painreliefmeds.com. Additional information on the company is available at www.premierbiomedical.com.
The company has several very important meetings scheduled over the next few weeks to discuss the introduction of their CBD products in medical settings, in an attempt to combat the opioid epidemic. “The opioid crisis is driving a resurgence of, and an interest in, opioid alternatives,” said Hartman, “and we believe we have the most effective alternatives. Our products are all non-habit forming, drug test safe, all-natural, fifty-state legal, and we believe that they are going to benefit the public, not only from a stock price standpoint, but from the position of all-natural pain relief.”
The company is abysmally undervalued, and plans to complete a reverse split in the upcoming month. Hartman believes that this move will benefit stockholders and make BIEI a very attractive stock to investors.
Listen to the interview’s full audio (link below) to hear more about Premier Biomedical’s reverse split decision, new distribution reach, and the science that allows CBD to be an effective alternative to opioids.
About Premier Biomedical, Inc.
We are a research-based company that intends to discover and develop medical treatments for humans. We have a three-fold corporate focus: (i) develop and market pain management products, (ii) develop our proprietary Sequential-Dialysis Technique to target cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia and other life-threatening cancers, and (iii) develop our proprietary drug candidate Feldetrex, a potential treatment for Multiple Sclerosis, Fibromyalgia, Neuropathic Pain and Traumatic Brain Injury. Our focus recently has been on our pain management products. We are engaged in several discussions to find a suitable partner to work with us on the anti-cancer drug development.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the under-valued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/